TCE2 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Celldex Therapeutics Inc

Watchlist Manager

Watchlist

Price: 36.02 EUR 2.24% Market Closed

Market Cap: €1.7B

C	Celldex Therapeutics Inc SWB:TCE2	US
	Nanya Technology Corp TWSE:2408	TW
	Chocoladefabriken Lindt & Spruengli AG OTC:COCXF	CH
	US Gold Corp NASDAQ:USAU	US
	Zignago Vetro SpA F:ZVB	IT
	AVer Information Inc TWSE:3669	TW
T	Thayer Ventures Acquisition II Corp NASDAQ:TVAI	US

Profitability Summary

Celldex Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-206,220%

Negative 3Y Average Operating Margin

-26,254%

Declining Operating Margin

-3,085% > -206,220%

Negative Net Margin

-190,221%

Negative 3Y Average Net Margin

-24,019%

Declining Net Margin

-2,851% > -190,221%

Negative Free Cash Flow Margin

-153,231%

Negative 3Y Average Free Cash Flow Margin

-19,514%

Declining Free Cash Flow Margin

-2,241% > -153,231%

Negative ROE

-44%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-432%

Declining ROIC

-318% > -592%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.